Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Paradigm Biopharmaceuticals Ltd. has submitted the final Phase 3 protocol for its knee osteoarthritis treatment to the US FDA, marking a significant milestone towards initiating trials in early 2025. The company has also reported a quarterly cash outflow of $4.72 million, well below its projected $7 million, and anticipates a substantial R&D rebate to support its ongoing activities. These developments position Paradigm favorably for future regulatory success and potential shareholder value creation.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
